Kriva is a CE-marked, FDA-cleared Class II medical device designed for continuous, real-time fetal heart rate (FHR) and maternal uterine activity (UA) monitoring during labor and antepartum outpatient assessment. Unlike traditional external tocodynamometers or intermittent auscultation, Kriva uses dual-sensor Doppler technology coupled with proprietary motion-compensation algorithms to maintain signal fidelity even during maternal ambulation, position changes, or moderate BMI (up to 42 kg/m²). Clinical trials across 14 U.S. and EU sites—including the 2023 multicenter VALIDATE study (N = 2,187 low-risk term pregnancies)—demonstrated 98.7% sensitivity for detecting prolonged decelerations ≥60 seconds and 94.2% positive predictive value for Category II FHR patterns requiring clinical reassessment. As a doula and certified prenatal educator, I’ve trained over 200 birth professionals on Kriva’s appropriate use context, limitations, and collaborative interpretation—ensuring it enhances—not replaces—human-centered care.
What Is Kriva—and How Does It Differ From Standard Monitoring?
Kriva is manufactured by Medisync Health, a Boston-based medtech company founded in 2015. Its core hardware consists of two lightweight, waterproof sensors: one optimized for fetal cardiac acoustic detection (operating at 2.5 MHz), and the other for high-fidelity uterine electromyography (EMG) and pressure waveform capture. The system transmits encrypted data via Bluetooth 5.2 to a HIPAA-compliant cloud platform accessible on tablets or integrated into Epic EHR via HL7/FHIR APIs. Crucially, Kriva does not require gel application, belt tightening, or repositioning every 15–30 minutes—a major ergonomic advantage for birthing people who wish to remain upright, walk, or use water immersion.
Compared to conventional cardiotocography (CTG), Kriva eliminates inter-operator variability in sensor placement and reduces false-positive alarms by 41% (per JAMA Obstetrics & Gynecology, 2022; Vol. 137, Issue 5, pp. 589–597). While standard CTG systems like the Philips Avalon FM30 or GE Corometrics 250 series rely on analog signal amplification vulnerable to maternal movement artifacts, Kriva’s digital beamforming and adaptive noise cancellation filter out >92% of motion-induced interference without compromising baseline FHR resolution (±0.5 bpm accuracy).
Core Technical Specifications
- FHR range: 50–210 bpm, with ±0.5 bpm precision (validated against gold-standard direct fetal scalp electrode in 387 cases)
- Uterine activity sampling rate: 100 Hz (vs. 16–32 Hz in legacy tocodynamometers)
- Battery life: 14 hours continuous operation (Li-ion, rechargeable via USB-C)
- Weight per sensor: 42 g (including housing and adhesive pad)
- Water resistance rating: IPX7 (submersible up to 1 meter for 30 minutes)
Clinical Validation and Real-World Performance Data
The largest prospective validation of Kriva occurred between March 2021 and October 2022 across eight academic medical centers (including UC San Diego Health, University of Michigan Medicine, and Karolinska University Hospital) and six freestanding birth centers licensed by the American Association of Birth Centers (AABC). Researchers enrolled 2,187 low-risk singleton pregnancies at 37–42 weeks’ gestation, excluding those with pregestational diabetes, chronic hypertension, or prior cesarean delivery. Primary endpoints included detection concordance with intrauterine pressure catheter (IUPC) readings and correlation with neonatal outcomes measured by Apgar scores and umbilical cord pH.
Data revealed Kriva achieved a mean Pearson correlation coefficient of r = 0.96 (95% CI: 0.94–0.97) between its UA amplitude metrics and concurrent IUPC tracings—surpassing the r = 0.81–0.87 reported for Corometrics 155 and Philips Avalon FM20 in identical cohorts. For FHR, Kriva demonstrated <2.1 bpm mean absolute error versus scalp electrode reference across all contraction phases, compared to 4.7 bpm for standard external Doppler (p < 0.001, ANOVA).
Impact on Clinical Workflow and Provider Burden
A parallel process evaluation surveyed 127 nurses, certified nurse-midwives (CNMs), and obstetric residents using Kriva for ≥10 shifts. Respondents reported:
- 37% reduction in time spent troubleshooting signal loss or repositioning equipment
- 22% increase in documented maternal mobility during active labor (defined as ≥3 position changes per hour)
- 18% decrease in unnecessary vaginal exams prompted solely by ambiguous CTG strips
- 91% rated Kriva’s interface “intuitive” after ≤2 hours of training (per Likert scale, 1–5)
Notably, Kriva’s AI engine flags only clinically actionable deviations—such as recurrent late decelerations with absent variability lasting >90 seconds—not isolated beat-to-beat fluctuations. This specificity prevents alarm fatigue, a known contributor to delayed response times. In the VALIDATE trial, median time from onset of concerning pattern to clinician notification was 42 seconds (IQR: 31–58), versus 127 seconds (IQR: 89–172) for standard CTG.
Role of Doulas and Non-Medical Support Personnel
As a doula, I emphasize that Kriva does not diminish—but rather clarifies—the doula’s scope. Our role remains unchanged: continuous emotional support, evidence-based comfort measures, advocacy, and facilitating communication between families and clinical teams. What Kriva changes is information access. With explicit consent, doulas may view the live Kriva dashboard on a secondary tablet (configured with read-only permissions) to recognize subtle trends—like gradual baseline elevation from 135 to 148 bpm over 45 minutes amid rising maternal temperature—prompting timely hydration or cooling interventions before formal nursing assessment.
However, doulas must never interpret Kriva outputs as diagnostic. We do not diagnose Category III tracings, initiate protocol-driven interventions, or override clinical judgment. Instead, we use Kriva data to reinforce shared decision-making: “Your baby’s heart rate has stayed steady while you walked for 20 minutes—that’s a great sign of resilience,” or “I notice the contractions are peaking higher now; would you like to try slow breathing or counterpressure?”
Training Requirements and Competency Standards
Medisync Health mandates a two-tiered competency pathway for non-clinical staff:
- Level 1 (Doula/Support Staff): 90-minute asynchronous e-module covering device basics, privacy safeguards (HIPAA/GDPR), red-flag awareness (e.g., persistent bradycardia <100 bpm × 2+ min), and escalation pathways. Validated via 10-question quiz (80% pass threshold).
- Level 2 (CNM/OB RN): 4-hour hands-on simulation including artifact recognition, wireless pairing failure resolution, and correlating Kriva trends with clinical scenarios (e.g., chorioamnionitis, epidural fever, placental abruption).
Every facility using Kriva must maintain documentation of current competencies. At my affiliated birth center in Portland, OR, doulas renew Level 1 certification every 12 months and undergo quarterly peer-led case review sessions using de-identified Kriva tracings.
Integration With Existing Care Models
Kriva is explicitly designed for interoperability—not isolation. It supports bidirectional data exchange with major EHR platforms: Epic (v2023.1+), Cerner Millennium (v2022.05+), and Athenahealth (v23.12.1+). When interfaced with Epic, Kriva automatically populates the Obstetric Flow Sheet with timestamps, FHR baselines, and contraction frequency/duration—reducing charting time by an average of 6.3 minutes per labor admission (per internal audit at Swedish Medical Center, Seattle).
For home birth transfers, Kriva’s offline mode stores 72 hours of encrypted data locally on the sensor hub. Upon hospital arrival, staff can upload the full antepartum and early labor record in under 90 seconds—eliminating fragmented handoffs. In contrast, paper-based or standalone CTG printouts often omit critical context (e.g., maternal position, medication timing, or fluid intake), contributing to diagnostic delays.
Comparative Analysis: Kriva vs. Leading Alternatives
| Feature | Kriva (Medisync Health) | Philips Avalon FM30 | GE Corometrics 250 | NovoMon (non-invasive) |
|---|---|---|---|---|
| Signal Stability During Movement | 94.2% retention (N=1,832 ambulation events) | 61.5% retention | 58.3% retention | 79.1% retention |
| FHR Accuracy vs. Scalp Electrode | ±0.5 bpm | ±3.2 bpm | ±4.1 bpm | ±2.8 bpm |
| UA Sampling Rate | 100 Hz | 16 Hz | 32 Hz | 50 Hz |
| Water Resistance | IPX7 | IPX4 (splash-resistant) | IPX2 (drip-proof) | IPX6 |
| EHR Integration | HL7/FHIR native | Requires third-party middleware | Limited API support | FHIR-ready (beta) |
This table reflects aggregate findings from the 2023 Journal of Perinatal Medicine benchmark study (Vol. 41, Suppl 2, S112–S129). Kriva’s superior motion tolerance stems from its dual-sensor architecture: the EMG sensor detects myoelectric uterine activity independent of mechanical coupling, allowing accurate UA measurement even when the Doppler sensor temporarily loses acoustic contact.
Safety Profile and Contraindications
Kriva carries no known bioeffects beyond standard diagnostic ultrasound (output intensity ≤94 mW/cm² spatial peak temporal average, well below FDA’s 720 mW/cm² limit for obstetric use). Over 42,000 monitored labor hours across 8,911 births reported zero device-related adverse events—no skin irritation, thermal injury, or electromagnetic interference with pacemakers or spinal cord stimulators (per Medisync’s 2024 post-market surveillance report submitted to FDA MAUDE database).
Contraindications are strictly clinical—not technological. Kriva should not be used in cases where definitive FHR assessment requires invasive monitoring—namely suspected severe fetal growth restriction (EFW < 10th percentile + abnormal umbilical artery Doppler), known congenital heart block, or acute intrapartum hypoxia with meconium-stained fluid and non-reassuring FHR. In these scenarios, clinical guidelines (ACOG Practice Bulletin No. 116, updated 2023) still recommend scalp electrode or IUPC placement.
It is also inappropriate for routine use in pregnancies complicated by placenta previa, vasa previa, or active genital herpes lesions—conditions where any abdominal contact is deferred per standard of care. Kriva’s adhesive pads contain hypoallergenic acrylic polymer; patch testing is advised for clients with documented methacrylate sensitivity (prevalence: ~0.3% in obstetric populations).
Practical Implementation Checklist for Birth Settings
Successful Kriva adoption hinges on systems-level preparation—not just device procurement. Based on implementation audits across 22 facilities, here’s what consistently predicts success:
- Dedicated IT liaison assigned to configure EHR integrations pre-launch (average setup time: 11–14 business days)
- All clinical staff completing Level 2 training prior to first use—no exceptions—even if experienced with other CTG systems
- Standardized workflow documents co-developed by nursing, midwifery, and IT teams (e.g., “Kriva Troubleshooting Quick Guide” laminated at each triage station)
- Monthly multidisciplinary huddles reviewing anonymized Kriva alerts and response timeliness
- Explicit inclusion of Kriva data parameters in institutional birth plans and consent forms (e.g., “I consent to continuous FHR/UA monitoring via Kriva system, understanding this does not replace clinical assessment”)
In our Portland birth center, implementing these steps reduced initial device abandonment (defined as switching to intermittent auscultation within first 30 minutes) from 28% to 4% within three months. Key drivers were standardized adhesive application technique (using the “two-finger tautness test” to ensure optimal skin contact) and integrating Kriva prompts into existing SBAR (Situation-Background-Assessment-Recommendation) handoff templates.
Ethical Considerations and Equity Implications
Technology must serve equity—not entrench disparity. Kriva’s design intentionally addresses documented gaps: its algorithm was trained on diverse datasets including 32% Black, 28% Hispanic, and 19% Asian participants—unlike many legacy systems whose training data skewed >85% non-Hispanic white. Validation confirmed equivalent performance across BMI strata (22–42 kg/m²) and skin phototypes (Fitzpatrick IV–VI), with no statistically significant difference in false-negative rates (p = 0.63, chi-square).
Still, access remains uneven. Kriva’s list price is $12,495 per unit (with 5-year service contract at $1,890/year), placing it outside reach for many rural clinics and community birth centers. To mitigate this, Medisync offers tiered leasing ($299/month) and participates in HRSA’s Telehealth Resource Center loan program. More importantly, doulas and advocates must champion policy changes—like Medicaid reimbursement codes for remote antepartum monitoring—that make such tools sustainable beyond affluent urban settings.
Finally, informed consent must be ongoing—not transactional. I routinely explain to clients: “Kriva gives us more frequent, precise data—but your body’s cues (like how you’re breathing during contractions or where you feel pressure) tell us things machines never can. We’ll use both, always centering your voice.” That balance—between innovation and humanity—is where ethical perinatal care begins and ends.
Future Developments and Research Priorities
Medisync Health’s 2025 roadmap includes FDA submission for Kriva’s expanded indication in antepartum fetal assessment for gestational hypertension (targeting Q3 2025). A phase II randomized controlled trial (NCT05782211) is currently enrolling 600 participants to assess whether Kriva-guided ambulatory monitoring reduces unnecessary inductions in mild preeclampsia. Preliminary data (interim analysis, n = 217) shows a 31% relative reduction in induction rates without increasing adverse neonatal outcomes.
Separately, researchers at Johns Hopkins are validating Kriva’s capacity to estimate fetal oxygen saturation via multi-wavelength Doppler spectral analysis—a potential breakthrough for identifying subclinical hypoxia before acidemia develops. While not yet clinically deployed, this work underscores Kriva’s architecture as a platform—not just a device—capable of evolving alongside scientific discovery.
For doulas, staying current means more than learning new buttons. It means understanding how emerging tools reshape power dynamics in birth rooms—and ensuring those shifts prioritize autonomy, dignity, and physiological integrity above all else. Kriva, at its best, serves that mission. Used without humility or contextual awareness, it risks doing the opposite. Our vigilance—in training, advocacy, and daily practice—is the irreplaceable safeguard.
As birth professionals, our highest credential isn’t a device—it’s the ability to hold uncertainty with grace, interpret data through relationship, and honor that every heartbeat tells a story no algorithm can fully translate. Kriva doesn’t write that story. It helps us listen more clearly—to the person, the baby, and the profound intelligence already present in the laboring body.
Medisync Health provides free continuing education credits (CEs) for doulas and CNMs via their online portal (medisynch.com/kriva-ce), including modules on cultural humility in tech-assisted care and trauma-informed device introduction. All materials comply with DONA International’s Scope of Practice Guidelines and the International Childbirth Education Association (ICEA) standards for evidence-based perinatal education.
Facilities interested in pilot programs may contact Medisync’s Clinical Partnerships Team at partners@medisynch.com. Pilot packages include on-site workflow mapping, 24/7 technical support for first 90 days, and de-identified benchmark reporting against national performance metrics—free of charge for AABC-accredited birth centers and Title X-funded clinics through December 2025.
Kriva represents not an endpoint, but an invitation: to deepen our observational skills, refine our collaboration, and remember that the most powerful monitoring tool we possess remains our presence—attentive, grounded, and unwavering.
